Category Archives: high priced medicines

Unenforced, Bayh-Dole enables a federal offer to look the other way on price-gouging

The government’s failure to use its government license to practice and have practiced (=make, use, and sell) puts undue pressure on march-in to address nonuse and unreasonable use of inventions arising in work receiving federal support. NIST wants to gut … Continue reading

Posted in Bayh-Dole, high priced medicines, History, Vannever Bush | Tagged , , , , | Leave a comment

Being blunt about Bayh-Dole operations

Let’s be blunt. If you are a federal contractor and you don’t take/accept ownership of an invention arising in federally supported research or development, you have no Bayh-Dole obligations with regard to that invention. You do not have to get … Continue reading

Posted in Bayh-Dole, high priced medicines, Policy | Tagged , , , | Comments Off on Being blunt about Bayh-Dole operations

The Wall Street Journal publishes an editorial against using Bayh-Dole march-in for remdesivir

Sally Pipes has published an op/ed piece at the Wall Street Journal on Bayh-Dole and Gilead, “The Remdesivir Patent Isn’t State Property.” There is so much going on with Pipes’s work. We should take a closer look. First, the title … Continue reading

Posted in Bayh-Dole, high priced medicines, Policy | Tagged , , , | Comments Off on The Wall Street Journal publishes an editorial against using Bayh-Dole march-in for remdesivir

AUTM weighs in on march-in for remdesivir

AUTM has issued a statement on march-in with respect to remdesivir. To date, AUTM has never supported march-in. This new statement is no exception. Howard Bremer, an AUTM founder back when AUTM was SUPA, worked on the implementing regulations for … Continue reading

Posted in Bayh-Dole, high priced medicines, Policy | Tagged , , | Comments Off on AUTM weighs in on march-in for remdesivir